Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 5;69(Suppl 2):S66-S71.
doi: 10.1093/cid/ciz457.

Impact of 13-Valent Pneumococcal Conjugate Vaccine on Meningitis and Pneumonia Hospitalizations in Children aged <5 Years in Senegal, 2010-2016

Affiliations

Impact of 13-Valent Pneumococcal Conjugate Vaccine on Meningitis and Pneumonia Hospitalizations in Children aged <5 Years in Senegal, 2010-2016

Papa M Faye et al. Clin Infect Dis. .

Abstract

Background: Senegal introduced a 13-valent pneumococcal conjugate vaccine (PCV13) in October 2013, given at 6, 10, and 14 weeks of age. We document trends of meningitis and pneumonia after the PCV13 introduction.

Methods: From October 2010-October 2016, hospitalization data for clinical meningitis and pneumonia in children aged <5 years were collected from logbooks at a large, tertiary, pediatric hospital in Dakar. We used a set of predetermined keywords to define hospitalizations for extraction from hospital registers. We conducted a time-series analysis and compared hospitalizations before and after the PCV13 introduction, accounting for seasonality. The initial PCV13 uptake period (October 2013-September 2014) was considered to be transitional and was excluded.

Results: Over the 7-year period, 1836 and 889 hospitalizations with a discharge diagnosis of pneumonia and meningitis, respectively, occurred in children aged <5 years. In children aged <12 months, a small, significant reduction in pneumonia was observed post-PCV13 (-3.8%, 95% confidence interval [CI] -1.5 to -5.9%). No decline was observed among children aged 12-59 months (-0.7%, 95% CI -0.8 to 2.2%). Meningitis hospitalizations remained stable for children aged <12 months (1.8%, 95% CI -0.9 to 4.4%) and 12-59 months (-0.5%, 95% CI -3.6 to 2.6%).

Conclusions: We used data from 1 hospital to detect a small, significant reduction in all-cause pneumonia hospitalizations 2 years post-PCV13 introduction in infants; the same trend was not measurable in children aged 12-59 months or in meningitis cases. There is a need for continued surveillance to assess the long-term impact of sustained PCV13 use and to monitor how pneumococcus is causing disease in the meningitis belt.

Keywords: hospitalization data; meningitis; pneumococcal conjugate vaccine; pneumonia; vaccine impact.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Proportion of pneumonia hospitalizations among all hospitalizations, children 0 to 59 months, by month. Data are from the Centre Hospitalier National d’Enfants Albert Royer, October 2010-Qctober 2016. Abbreviation: PCV13, 13-valent pneumococcal conjugate vaccine.
Figure 2.
Figure 2.
Proportion of meningitis hospitalizations among all hospitalizations, children 0 to 59 months, by month. Data are from the Centre Hospitalier National d’Enfants Albert Royer, October 2010–October 2016. Abbreviation: PCV13, 13-valent pneumococcal conjugate vaccine.

Similar articles

Cited by

References

    1. Wahl B, O’Brien K, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type B disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health 2018; 6:e744–e757. - PMC - PubMed
    1. World Health Organization. Estimated Hib and pneumococcal deaths for children under 5 years of age. Available at: http://www.who.int/immunization/monitoring_surveillance/burden/estimates... Accessed 31 August 2018.
    1. Ba I, Ba A, Faye P, et al. Pediatric invasive pneumococcal disease in Senegal. Med Mal Infect 2015; 45:464–469. - PubMed
    1. World Health Organization. Pneumococcal conjugate vaccine for pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. Wkly Epidemiol Rec 2019; 94(8):85–104.
    1. Conklin L, Loo JD, Kirk J, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J 2014; 33(Suppl 2):S109–18. - PMC - PubMed

Publication types

MeSH terms

Substances